- Pressemitteilung BoxID 70525
4SC reports on positive results from a clinical phase I trial with cancer drug candidate 4SC-201
The first available study results prove that 4SC-201 can be administered safely, is highly tolerable and shows a particularly advantageous pharmacological profile. At advanced stages of this study (i.e. 4SC-201 given orally once daily at 600 mg and 800 mg), different cancers were seen to stabilise in several patients. In some of these cases, with an optional, prolonged treatment with 4SC-201 that went beyond the main therapy plan, to date the treatment period has already reached up to six months.
In this trial, being conducted at the Royal Marsden Hospital in Sutton near London, under the direction of Professor Dr. J. S. de Bono, patients who suffer from a progressed solid tumour disease or from malignant lymphomas can be accepted. They have received at least one previous standard therapy, or no standard therapy exists for them. To date, a total of 17 evaluable patients have been included in the trial.
The conclusion, and with it the final results of the trial, are expected shortly. It is on this basis that the enterprise plans to begin with different efficacy studies during clinical phase II tests on different tumour diseases in the coming year.
4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 77 employees, the company develops novel drug candidates against inflammatory diseases and cancer. 4SC AG utilises its patent protected platform, to create a sustainable project pipeline of drug candidates, which are to be developed up to clinical efficacy in early clinical phases ('proof of concept') and subsequently partnered with the pharmaceutical industry in return for advance and milestone payments as well as royalties. There are currently eight projects in the development pipeline and a rich pool of further discovery projects. Clinical phase IIa for the first project for the treatment of rheumatoid arthritis has already successfully been completed. An additional project for the treatment of various cancers is currently completing a clinical phase I trial. Further projects are in advanced pre-clinical stages.
Further information is to be found at www.4sc.com.
4SC-201 is an innovative substance from the histone deacetylase (HDAC) class of inhibitors. It concerns one of the drug candidates, which 4SC AG took over in July of this year from Nycomed, with the former designation BYK408740. Compared with other cancer drugs, which also block the HDAC enzyme, this candidate showed a particularly good pharmacokinetic profile upon oral application in previous test series. In addition, a very good safety profile and very good efficacy were observed with respect to its broad anti-tumour activity in preclinical models.
Diese Pressemitteilungen könnten Sie auch interessieren
, Gesundheit & Medizin, Magnosco GmbH
Ab sofort ergänzt Dr. Sebastian Ahlberg die Geschäftsführung des MedTech-Unternehmens Magnosco um Inga Bergen (Managing Director/CEO) und Thomas...
Angst ist natürlich. Der Körper wird in einen Alarmzustand versetzt und vor einer möglichen Gefahr gewarnt. Beruhigt sich die Situation wieder,...